Bernhard Hampl, PH.D.
CEO Advisory Board Member
Bernhard Hampl, Ph.D. is the former Co-Chairman of the board of directors of Softbox (GPP II) and Cytovance (GPP I).
Dr. Hampl was the President and CEO of Eon Labs. Under his leadership, sales grew from $20 million to $435 million without acquisitions. During the four-year period from 2000 to 2004, Eon had the most Abbreviated New Drug Applications (“ANDAs”) approved among all US generic companies. Shares of Eon Labs appreciated 350% from the 2001 IPO until the 2005 acquisition by Novartis for $2.8 billion. After the acquisition, he became the CEO of the Sandoz Division of Novartis.
He is also currently Executive Chairman of APP/Fresenius Kabi. Dr. Hampl was previously an executive board member for the Generic Pharmaceutical Association.
He received his Ph.D. from the Ludwig Maximilian University of Munich in Germany.